StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Friday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of Check-Cap stock opened at $1.10 on Friday. The company has a market cap of $6.44 million, a P/E ratio of -0.37 and a beta of 0.25. The firm has a fifty day moving average of $0.96 and a two-hundred day moving average of $1.54. Check-Cap has a one year low of $0.56 and a one year high of $3.45.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.